AQILION AB and Immunscape AB initiated a joint early project in oncology and autoimmune diseases in the spring of 2019. The point of departure was to create a drug candidate that the parties would develop and test further in a joint feasibility study. The parties have now agreed to discontinue the project.
“Collaborating with Immunscape has been highly rewarding and we continue to appreciate their expertise, from which we have gained great professional benefit. The feasibility study produced good technical results and new intangible assets, but external factors have led to declining interest in the continued commercial development of the project. We have therefore agreed to terminate our collaborative effort. It is extremely important for us to have the courage to start innovative projects, but also to have the courage to close those in which Aqilion cannot continue to create value, even if it is disappointing not to reach all the way to our goal,” says Sarah Fredriksson, CEO of AQILION AB.
“We have appreciated the interactions with Aqilion and would like to thank them for their commitment to the project. Our collaboration with Aqilion has allowed us to advance our understanding of the drug targets in the project, which helps us to explore new uses of the compounds as potential treatments for certain cancers,” says Lars Öhman, CEO of Immunscape AB.
Aqilion is a biotechnology company focused on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immunological reactions such as autoimmunity. The company is primarily active in the early phases of drug development, from the idea stage to early clinical development.
Aqilion combines big pharma experience with an entrepreneurial mindset and drive. The company’s experienced team and board have previously brought medicinal products to market and have solid business development skills from innovative biotech and pharma companies.
AQILION AB is a Swedish privately held company headquartered in Helsingborg. www.aqilion.com